Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans.
Myron H Weinberger
https://pubmed.ncbi.nlm.nih.gov/12147930/Actively Recruiting
Led by Vanderbilt University Medical Center · Updated on 2026-11-04
20
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating salt sensitivity of blood pressure SSBP, a condition linked to hypertension and increased risks of heart attack, stroke, heart failure, and kidney disease. This phase 2 clinical trial explores how immune cells contribute to SSBP, particularly focusing on the role of isolevuglandins IsoLGs produced by myeloid cells. The study evaluates the potential of 2-hydroxybenzylamine 2-HOBA, an IsoLG scavenger, to reduce endothelial dysfunction and immune cell activation that may perpetuate salt sensitivity. Participants with confirmed salt-sensitive blood pressure will undergo a 12-week, randomized, double-blind, placebo-controlled, 2x2 crossover study. They will receive either 2-HOBA 500 mg three times daily or placebo for 4 weeks, followed by a 4-week washout, then switch to the other treatment for 4 weeks. Salt loading and depletion protocols, including controlled diets and saline infusions, will be used to measure blood pressure responses and immune activity at specific weeks. Throughout the study, participants will have ambulatory blood pressure monitoring, blood and urine collections for laboratory analyses, and assessments of immune cell activation and vascular function. Procedures include flow-mediated vasodilation FMD ultrasound and endothelial cell harvesting. Researchers will measure changes in systolic blood pressure, oxidative stress markers, inflammatory cytokines, and endothelial health. The trial spans from week 0 to 12, with evaluations at weeks 0, 4, 8, and 12.
CONDITIONS
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
A
Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A.
C
Cindy Mambungu, LPN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Vanderbilt University Medical Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 2 HOBA | Placebo |
|---|---|---|
| What it is | An investigational drug scavenger that targets isolevuglandin adducts to study salt‑sensitive blood pressure | An inert placebo used as the comparator in the crossover periods |
| Role in trial | Tested as the active investigational condition in one treatment period | Used as control condition in a separate period for within‑participant comparison |
| Primary use or purpose | Studied to assess its effect on salt sensitivity of blood pressure and immune cell activation | Serves as an inactive control to evaluate the effect of 2HOBA |
| Administration or procedure | Participants receive oral 2‑hydroxybenzylamine during one treatment period following drug wash‑out | Participants receive placebo during a treatment period after wash‑out |
| Evidence status | Functional effects on salt sensitivity and immune activation are under investigation in a controlled trial | Serves as baseline comparator; no therapeutic effect |
| Important risks | Safety profile under study; risks not yet established | No pharmacological risks expected from placebo |
| Important limitations | Small sample size and crossover design may limit generalizability | Crossover within same participants may carry carry‑over or period effects |
| Patient impact | Potential to reduce salt‑sensitive blood pressure and modulate immune activation if effective | No expected clinical benefit beyond baseline monitoring |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - 4 weeks
Participants receive either 2-HOBA or placebo three times daily for 4 weeks while maintaining usual diet until protocol start. Blood pressure and immune activity are monitored, including salt loading and depletion procedures.
Visits at weeks 0 and 4 with ambulatory monitoring and sample collections
Duration - 4 weeks
Participants stop the study drug or placebo for 4 weeks to clear effects before switching treatments.
Visits during washout may include blood pressure monitoring
Duration - 4 weeks
Participants receive the alternate treatment (placebo or 2-HOBA) three times daily for 4 weeks with continued monitoring and assessments as in Period 1.
Visits at weeks 8 and 12 with ambulatory monitoring and sample collections
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Myron H Weinberger
https://pubmed.ncbi.nlm.nih.gov/12147930/M H Weinberger, N S Fineberg, S E Fineberg...
https://pubmed.ncbi.nlm.nih.gov/11230313/Lale A Ertuglu, Mert Demirci, Ashley L Mutchler...
https://pubmed.ncbi.nlm.nih.gov/41052782/M H Weinberger, J Z Miller, F C Luft...
https://pubmed.ncbi.nlm.nih.gov/3522418/Lale A Ertuglu, Ashley Pitzer Mutchler, Fernando Elijovich...
https://pubmed.ncbi.nlm.nih.gov/37534363/M H Weinberger, N S Fineberg
https://pubmed.ncbi.nlm.nih.gov/1860713/Lale A Ertuglu, Ashley Pitzer Mutchler, Sydney Jamison...
https://pubmed.ncbi.nlm.nih.gov/37675576/M H Weinberger
https://pubmed.ncbi.nlm.nih.gov/1879381/F C Luft, J Z Miller, C E Grim...
https://pubmed.ncbi.nlm.nih.gov/1846122/Vanderbilt University Medical Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborating Sponsor